DUBLIN, Nov. 28, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Pulmonary Drug Delivery Systems Market 2015-2019" report to their offering.
Pulmonary delivery of drugs leads to the deposition of drugs in the lungs and subsequent local or systemic therapeutic activity. The pulmonary route of administration for the non-invasive delivery of drugs is mostly preferred because of the large surface area for absorption, high blood circulation, and high permeability rate. Pulmonary drug delivery offers various advantages over peroral routes, such as bypass of hepatic first-pass metabolism, quick onset of action, and low enzymatic activity.
Pulmonary delivery of drugs can be achieved by intranasal administration or oral inhalative administration, the latter being more effective. Oral inhalative administration includes intratracheal inhalation and intratracheal instillation. Oral inhalation delivers the aerosolized drug using devices such as MDIs (or pMDIs), PDIs, and nebulizers. Drugs administered by this route are deposited in the respiratory tract via inertial impaction, gravitational sedimentation, and diffusion. The effective delivery of drugs via the pulmonary route requires an optimized combination of drug, its formulation, and device.
The analysts forecast the Global Pulmonary Drug Delivery Systems market to grow at a CAGR of 8.90 percent over the period 2014-2019.
This report covers the present scenario and the growth prospects of the Global Pulmonary Drug Delivery Systems market for the period 2015-2019. To calculate the market size, the report considers the revenue from the sales of various pulmonary drug delivery systems intended for oral inhalation including:
- MDIs (or pMDIs)
The report, the Global Pulmonary Drug Delivery Systems Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Pulmonary Drug Delivery Systems market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
An increase in online marketing services is one major trend upcoming in the market. These services increase awareness regarding the products concerned, which increases the sales of these devices, thereby driving the market.
According to the report, an increase in the prevalence and incidence of respiratory diseases such as asthma and COPD is one of the major drivers of the market, and this is expected to increase the patient population requiring pulmonary drug delivery. Consequently, this is expected to increase the market revenue of pulmonary delivery systems. Any drug that can cater to these needs is expected to enhance the growth of the market during the forecast period
Further, the report states that intense market competition is one of the major challenges in the market. Medium and small-sized companies concentrate on a single product line in a specific geographic region and hence, have also intensified the market competition.
Key Topics Covered:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Market Research Methodology
06. Market Landscape
07. Market Segmentation by Product Type
11. Geographical Segmentation
12. Buying Criteria
13. Market Growth Drivers
14. Drivers and their Impact
15. Market Challenges
16. Impact of Drivers and Challenges
17. Market Trends
18. Trends and their Impact
19. Vendor Landscape
20. Key Vendor Analysis
21. Other Reports in this Series
- 3M Health Care
- Actelion Pharmaceuticals
- Allied Healthcare Products
- Boehringer Ingelheim
- Briggs Healthcare
- Clement Clarke International
- DeVilbiss Healthcare
- Drive Medical Design and Manufacturing
- GF Health Products
- Heyer Medical
- PARI Medical Holding
- Philips Healthcare
- Salter Labs
For more information visit http://www.researchandmarkets.com/research/8jbp7n/global_pulmonary
Media Contact: Laura Wood , +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets